Now PlayingEP. 1 Advancing IgA Nephropathy Care: Emerging Therapies, Unmet Needs, and Economic Considerations
EP. 3 Pathogenesis of IgA Nephropathy: The 4-Hit Cascade, A Proliferation-Inducing Ligand (APRIL), and cytokines
Fixing the Mental Health System: Burnout, Advocacy, and the Case for Team-Based CareByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MDPublished: July 7th 2026 | Updated: June 16th 2026
The Ripple Effect of Coverage Delays: Patient Harm and Preventable Crises in PsychiatryByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MDPublished: July 7th 2026 | Updated: June 16th 2026
Access and Adherence: Navigating Insurance Coverage and Real-World Barriers to Biomarker Testing in Extrapulmonary Neuroendocrine CarcinomaByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MDJuly 6th 2026
Tracking Progress and Bridging Guideline Gaps in Atopic Dermatitis CareByAngela J. Lamb, MDJuly 6th 2026
Clinical Pathways, Barriers, and Infrastructure Needs in Biomarker Testing for Extrapulmonary Neuroendocrine CarcinomaByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MDJuly 6th 2026
